Title : Adherence of type ii diabetics in morocco: Cross-cultural adaptation and validation of a measurement tool
Type 2 diabetes is a disease of great frequency and is a major public health dilemma. The International Diabetes Federation (IDF) reports that in 2013 more than 382 million people were diabetic or 8.3% of the world population. In our country Morocco, studies conducted on small samples show figures around 2% in adults aged 20 and over. However, as age advances, the prevalence of diabetes increases to 5 to 6%. Nationally, a Ministry of Health survey conducted in 2000 among a random sample of 2000 Moroccans aged 20 years and older in 100 Moroccan municipalities reported an overall prevalence of diabetes of 6.6%. The International Diabetes Federation reported 1.5 million Moroccan adults aged 20 years and older with diabetes in 2010 and predicts 2.5 million by 2030.
The diabetic patient plays a pivotal role in the management of his or her disease, which requires him or her to make a series of lifestyle adjustments as soon as the diagnosis is made. The application of health recommendations is described as therapeutic adherence, which refers to the patient's willingness to actively participate in the treatment or health behaviors established in collaboration with the health care professional. Non-adherence to therapy is a frequent phenomenon in patients with type 2 diabetes, which has an important impact on the management of this disease.
In Morocco, and to our knowledge, we do not have validated tools that will allow us to measure therapeutic compliance in type 2 diabetics.
It is in this perspective that we have conducted this work, the main objective of which is to translate and validate in the Moroccan context a tool for measuring compliance in these patients. To carry out this work, the method adopted is translation and counter-translation, in order to validate this tool GMAS (the General Medication Adherence Scale), which aims specifically at the evaluation of therapeutic adherence in our target population. This will allow public authorities and practitioners to identify, among patients, those at high risk and to intervene in order to improve their adherence.